The Cooper Companies with ticker code (COO) have now 13 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 560 and 400 with the average target price sitting at 465.46. With the stocks previous close at 385.2 this would imply there is a potential upside of 20.8%. The 50 day moving average now sits at 401.31 and the 200 day MA is 409.27. The company has a market cap of $19,679m. Find out more information at: https://www.coopercos.com
The potential market cap would be $23,780m based on the market concensus.
The Cooper Companies, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women’s health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies was founded in 1958 and is headquartered in San Ramon, California.
